Next Article in Journal
Design, Synthesis, and Biological Evaluation of PKD Inhibitors
Previous Article in Journal
Live Cell in Vitro and in Vivo Imaging Applications: Accelerating Drug Discovery
Previous Article in Special Issue
Nano Delivers Big: Designing Molecular Missiles for Cancer Therapeutics
Pharmaceutics 2011, 3(2), 171-185; doi:10.3390/pharmaceutics3020171

Nanotechnology and Drug Delivery: An Update in Oncology

 and 2,*
Received: 6 February 2011 / Accepted: 31 March 2011 / Published: 14 April 2011
(This article belongs to the Special Issue Nanotechnology in Drug Delivery)
View Full-Text   |   Download PDF [189 KB, updated 15 April 2011; original version uploaded 14 April 2011]   |   Browse Figure
Abstract: The field of nanotechnology has exploded in recent years with diverse arrays of applications. Cancer therapeutics have recently seen benefit from nanotechnology with the approval of some early nanoscale drug delivery systems. A diversity of novel delivery systems are currently under investigation and an array of newly developed, customized particles have reached clinical application. Drug delivery systems have traditionally relied on passive targeting via increased vascular permeability of malignant tissue, known as the enhanced permeability and retention effect (EPR). More recently, there has been an increased use of active targeting by incorporating cell specific ligands such as monoclonal antibodies, lectins, and growth factor receptors. This customizable approach has raised the possibility of drug delivery systems capable of multiple, simultaneous functions, including applications in diagnostics, imaging, and therapy which is paving the way to improved early detection methods, more effective therapy, and better survivorship for cancer patients.
Keywords: drug delivery systems; nanotechnology; cancer; passive targeting; active targeting drug delivery systems; nanotechnology; cancer; passive targeting; active targeting
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |

MDPI and ACS Style

Jones, T.; Saba, N. Nanotechnology and Drug Delivery: An Update in Oncology. Pharmaceutics 2011, 3, 171-185.

AMA Style

Jones T, Saba N. Nanotechnology and Drug Delivery: An Update in Oncology. Pharmaceutics. 2011; 3(2):171-185.

Chicago/Turabian Style

Jones, Tait; Saba, Nabil. 2011. "Nanotechnology and Drug Delivery: An Update in Oncology." Pharmaceutics 3, no. 2: 171-185.

Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert